Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Barr, D. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ACADEMIA AND CLINIC

The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?

right arrow Donald A. Barr, MD, PhD

6 December 2005 | Volume 143 Issue 11 | Pages 809-815

Recent research has identified genetic traits that can be used in a laboratory setting to distinguish among global population groups. In some genetic analyses, the population groups identified resemble groups that are historically categorized as "races." On the basis of these associations, some researchers have argued that a patient's race can be used to predict underlying genetic traits and from these traits, the expected outcomes of treatment. Others have questioned the use of race in this way, arguing that racially defined groups are so heterogeneous that predictions of individual characteristics derived from group averages are bound to be problematic.

Practitioners today face the dilemma of translating this scientific debate into clinical decisions made 1 patient at a time. Is it or is it not appropriate to use a patient's self-identified "race" to help decide treatment?

In contrast to the global population groups identified by genetic studies, the U.S. population has experienced substantial genetic admixture over time, weakening our ability to distinguish groups on the basis of meaningful genetic differences. Nonetheless, many researchers have suggested that these differences are still sufficient to identify racially specific uses for pharmaceutical and other treatments. A review of recent research on the treatment of hypertension and congestive heart failure finds that race-specific treatments of this type carry a substantial risk for treating patients—black or white—inappropriately, either by withholding a treatment that may be effective or by using a treatment that may be ineffective. Only by moving beyond historical concepts of "race" to examining a patient's individual socioeconomic, cultural, behavioral, and ancestral circumstances can a practitioner select the treatment that is most likely to be effective and in doing so, can best serve that patient's needs.

Author and Article Information
space

From Stanford University, Stanford, California.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Donald A. Barr, MD, PhD, Department of Sociology, Stanford University, Building 120, MC 2047, Stanford, CA 94305-2047; e-mail, barr{at}stanford.edu.




This article has been cited by other articles:


Home page
Am J EpidemiolHome page
R. W. Grant
Invited Commentary: Untangling the Web of Diabetes Causality in African Americans
Am. J. Epidemiol., August 15, 2007; 166(4): 388 - 390.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2005 by the American College of Physicians.